Granules India Completes FDA cGMP Audit at Chantilly Facility

Granules India Limited has completed a routine current Good Manufacturing Practices (cGMP) audit at its Chantilly, Virginia facility, conducted by the US Food and Drug Administration (FDA). The inspection took place from March 30 to April 3, 2026, and resulted in four Form 483 observations. These observations pertain to procedural matters, and no data integrity-related issues were identified during the audit. This inspection marks the second FDA review at the Chantilly site within the past year.

The filing does not disclose specific financial terms or amounts related to the audit process. Granules India Limited has not reported any financial penalties or costs associated with the observations noted by the FDA. The company has committed to addressing the procedural observations within the timelines stipulated by the FDA to ensure continued compliance with regulatory standards.

The scope of the audit at the Chantilly facility included a comprehensive review of the manufacturing processes and procedures in place. The FDA’s observations were limited to procedural aspects, indicating that the facility’s operational integrity remains intact. Granules India Limited has expressed its commitment to maintaining high standards of quality, safety, and regulatory compliance across its operations.

The Chantilly facility is part of Granules Pharmaceuticals, Inc., a wholly-owned subsidiary of Granules India Limited. This site plays a critical role in the company’s manufacturing capabilities, contributing to its presence in regulated markets. The facility’s compliance with FDA standards is crucial for the company’s operations in the United States, a key market for its pharmaceutical products.

The timeline for addressing the FDA’s observations has not been explicitly stated in the filing. However, Granules India Limited has indicated that it will respond to the observations within the stipulated timelines set by the FDA. The company aims to resolve the procedural issues to ensure ongoing compliance with regulatory requirements.

Granules India Limited is a vertically integrated pharmaceutical company involved in the manufacturing of Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs), Finished Dosages (FDs), and Peptides CDMO. The company operates 10 manufacturing facilities, including sites in India, the USA, and Switzerland, and holds regulatory approvals from various international bodies. Granules India is committed to operational excellence and quality in its global pharmaceutical operations.